Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications

被引:63
|
作者
Nakamura, Akinori [1 ]
Takeda, Shin'ichi [2 ]
机构
[1] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Nagano 3908621, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Kodaira, Tokyo 1878502, Japan
关键词
EXON-SKIPPING THERAPY; SKELETAL-MUSCLE; SYSTEMIC DELIVERY; CANINE MODEL; MDX MOUSE; EXPRESSION; GENE; MICE; DEGENERATION; RESTORATION;
D O I
10.1155/2011/184393
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disorder characterized by muscle wasting which is caused by mutations in the DMD gene. The DMD gene encodes the sarcolemmal protein dystrophin, and loss of dystrophin causes muscle degeneration and necrosis. Thus far, therapies for this disorder are unavailable. However, various therapeutic trials based on gene therapy, exon skipping, cell therapy, read through therapy, or pharmaceutical agents have been conducted extensively. In the development of therapy as well as elucidation of pathogenesis in DMD, appropriate animal models are needed. Various animal models of DMD have been identified, and mammalian (murine, canine, and feline) models are indispensable for the examination of the mechanisms of pathogenesis and the development of therapies. Here, we review the pathological features of DMD and therapeutic applications, especially of exon skipping using antisense oligonucleotides and gene therapies using viral vectors in murine and canine models of DMD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] THERAPEUTIC TARGETS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD)
    Brown, A. E.
    Sorbera, L. A.
    DRUGS OF THE FUTURE, 2013, 38 (06) : 395 - 406
  • [22] The role of pathological miRNAs in Duchenne and Becker muscular dystrophy
    Fiorillo, A.
    McCormack, N.
    Calabrese, K.
    Heier, C.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S148 - S148
  • [23] Duchenne Muscular Dystrophy Models Show Their Age
    Chamberlain, Jeffrey S.
    CELL, 2010, 143 (07) : 1040 - 1042
  • [24] Immunoproteasome in animal models of Duchenne muscular dystrophy
    Chen, Chiao-nan Joyce
    Graber, Ted G.
    Bratten, Wendy M.
    Ferrington, Deborah A.
    Thompson, LaDora V.
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2014, 35 (02) : 191 - 201
  • [25] Immunoproteasome in animal models of Duchenne muscular dystrophy
    Chiao-nan Joyce Chen
    Ted G. Graber
    Wendy M. Bratten
    Deborah A. Ferrington
    LaDora V. Thompson
    Journal of Muscle Research and Cell Motility, 2014, 35 : 191 - 201
  • [26] CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
    Chey, Yu C. J.
    Arudkumar, Jayshen
    Aartsma-Rus, Annemieke
    Adikusuma, Fatwa
    Thomas, Paul Q.
    WIRES MECHANISMS OF DISEASE, 2023, 15 (01):
  • [27] Neurobehavioral Characteristics of Children with Duchenne Muscular Dystrophy
    Donders, Jacobus
    Taneja, Chand
    CHILD NEUROPSYCHOLOGY, 2009, 15 (03) : 295 - 304
  • [28] Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
    Dominic J. Wells
    Journal of Muscle Research & Cell Motility, 2006, 27 : 387 - 398
  • [29] Common therapeutic advances for Duchenne muscular dystrophy (DMD)
    Salmaninejad, Arash
    Abarghan, Yousef Jafari
    Qomi, Saeed Bozorg
    Bayat, Hadi
    Yousefi, Meysam
    Azhdari, Sara
    Talebi, Samaneh
    Mojarrad, Majid
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2021, 131 (04) : 370 - 389
  • [30] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    DUBOWITZ, V
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    MUSCLE & NERVE, 1986, 9 (05) : 270 - 270